ArticleToxins2013
Three-fingered RAVERs: Rapid Accumulation of Variations in Exposed Residues of snake venom toxins.
Article in Toxins, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.
- Pooled it
- Antigenic divergence of cobra short-chain α-neurotoxins: Implications for regional antivenom effectiveness in Southeast Asia.PLoS neglected tropical diseases · 2026Article
- Ancient origin and dynamic evolution of bivalent spider toxins.Molecular biology and evolution · 2026Article
- Venom Variation as a Window into the Ecology and Evolution of Snakes.Integrative and comparative biology · 2026Review
- Molecular mechanisms underlying early functional divergence in snake venom inferred from the genomes of two pitviper lineages.BMC biology · 2025Article
- Lowly Expressed Toxin Transcripts in Poorly Characterized Myanmar Russell's Viper Venom Gland.Biotech (Basel (Switzerland)) · 2025Article
- Evolution of Phospholipase A2 in Bees and Flies.Ecology and evolution · 2025Article
- Make Acetylcholine Great Again! Australian Skinks Evolved Multiple Neurotoxin-Proof Nicotinic Acetylcholine Receptors in Defiance of Snake Venom.International journal of molecular sciences · 2025Article
- Variations in "Functional Site" Residues and Classification of Three-Finger Neurotoxins in Snake Venoms.Toxins · 2025Review
- Article
- Exploring the Venom Gland Transcriptome ofToxins · 2024Article
- Article
- Molecular Insights into the Low Complexity Secreted Venom of Calliactis polypus.Genome biology and evolution · 2024Article
- Selection Across the Three-Dimensional Structure of Venom Proteins from North American Scolopendromorph Centipedes.Journal of molecular evolution · 2024Article
- From birth to bite: the evolutionary ecology of India's medically most important snake venoms.BMC biology · 2024Article
- Review
- Using organ-on-a-chip technology to study haemorrhagic activities of snake venoms on endothelial tubules.Scientific reports · 2024Article
- Development of a membrane-disruption assay using phospholipid vesicles as a proxy for the detection of cellular membrane degradation.Toxicon: X · 2024Article
- Synthetic development of a broadly neutralizing antibody against snake venom long-chain α-neurotoxins.Science translational medicine · 2024Article
- Elusive elapids: biogeographic venom variation in Indian kraits and its repercussion on snakebite therapy.Frontiers in pharmacology · 2024Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three-finger toxins (3FTx) represent one of the most abundantly secreted and potently toxic components of colubrid (Colubridae), elapid (Elapidae) and psammophid (Psammophiinae subfamily of the Lamprophidae) snake venom arsenal. Despite their conserved structural similarity, they perform a diversity of biological functions. Although they are theorised to undergo adaptive evolution, the underlying diversification mechanisms remain elusive. Here, we report the molecular evolution of different 3FTx functional forms and show that positively selected point mutations have driven the rapid evolution and diversification of 3FTx. These diversification events not only correlate with the evolution of advanced venom delivery systems (VDS) in Caenophidia, but in particular the explosive diversification of the clade subsequent to the evolution of a high pressure, hollow-fanged VDS in elapids, highlighting the significant role of these toxins in the evolution of advanced snakes. We show that Type I, II and III α-neurotoxins have evolved with extreme rapidity under the influence of positive selection. We also show that novel Oxyuranus/Pseudonaja Type II forms lacking the apotypic loop-2 stabilising cysteine doublet characteristic of Type II forms are not phylogenetically basal in relation to other Type IIs as previously thought, but are the result of secondary loss of these apotypic cysteines on at least three separate occasions. Not all 3FTxs have evolved rapidly: κ-neurotoxins, which form non-covalently associated heterodimers, have experienced a relatively weaker influence of diversifying selection; while cytotoxic 3FTx, with their functional sites, dispersed over 40% of the molecular surface, have been extremely constrained by negative selection. We show that the a previous theory of 3FTx molecular evolution (termed ASSET) is evolutionarily implausible and cannot account for the considerable variation observed in very short segments of 3FTx. Instead, we propose a theory of Rapid Accumulation of Variations in Exposed Residues (RAVER) to illustrate the significance of point mutations, guided by focal mutagenesis and positive selection in the evolution and diversification of 3FTx.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.